FDA: ‘Real Water’ Alkaline Water May Be Linked to Hepatitis Outbreak
FDA is in beginning stages of investigation; there may be more products connected to hepatitis outbreak
Hepatitis
Updates to the 2021 Adult Immunization Schedule
The ACIP emphasizes the importance of routine vaccinations during the pandemic to prevent diseases.
FDA to Review 3-Antigen Prophylactic Hepatitis B Vaccine
The vaccine candidate consists of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus.
Use of Direct Acting Antivirals With Potent Inducers Examined in Case Series
While DAAs have improved the treatment of chronic HCV infection by eliciting higher rates of sustained virologic response, they also interact with a number of agents that could potentially limit their effectiveness.
CDC Guidance Issued for Testing, Management of HCP Exposed to Hep C
Baseline testing for HCP should be conducted as soon as possible after exposure, ideally within 48 hours
Mavyret Labeling Update Includes Data on HCV Genotype 3b Infection, PWID
The VOYAGE-1 and VOYAGE-2 trials included HCV genotype 1, 2, 3, 4, or 6 infected patients with cirrhosis (VOYAGE-1) or compensated cirrhosis (VOYAGE-2) who were treatment-naive or PRS ([peg]interferon, ribavirin and/or sofosbuvir) treatment-experienced.
Epclusa Approved for Pediatric Patients with Chronic Hepatitis C Infection
Epclusa is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.
Risk for Liver Cancer Down With Low-Dose Aspirin in Hepatitis B, C
Risk for 10-year liver-related mortality also lower among aspirin users with chronic hepatitis B or C.
Harvoni, Sovaldi Approved for Younger Patients With Chronic HCV
The Food and Drug Administration (FDA) has approved Harvoni (ledipasvir and sofosbuvir; Gilead) and Sovaldi (sofosbuvir; Gilead) for use in younger patients with chronic hepatitis C virus (HCV). Specifically, Harvoni is now indicated for use in patients 3 years of age and older with: HCV genotypes 1, 4, 5, or 6 infection without cirrhosis or…
FDA: Cases of Serious Liver Injury Reported With Certain HCV Agents
FDA) is warning healthcare professionals that cases of liver decompensation, including liver failure and death, have been linked to certain hepatitis C drugs administered to patients with moderate to severe hepatic impairment.
